-
Tarsus Pharmaceuticals' TP-03 Hits Primary, Secondary Endpoints In Demodex Blepharitis Study
Monday, June 21, 2021 - 7:33am | 315Read More...Tarsus Pharmaceuticals Inc (NASDAQ: TARS) has reported topline data from Phase 2b/3 Saturn-1 trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%) in patients with Demodex blepharitis. 81% of patients achieved a significant, clinically meaningful collarette cure...
-
Leerink Swann Raises Inspire Pharmaceuticals (ISPH) Price Target To $10
Monday, March 8, 2010 - 12:02pm | 148Read More...Leerink Swann analyst Joseph P. Schwartz reiterated his Outperform rating for shares of Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH) and raised the price target from $8 to $10. Swann discussed the implications of Inspire Pharmaceuticals' AzaSite product having entered into Phase II trials to treat...
